AU8700998A - Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease - Google Patents

Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease

Info

Publication number
AU8700998A
AU8700998A AU87009/98A AU8700998A AU8700998A AU 8700998 A AU8700998 A AU 8700998A AU 87009/98 A AU87009/98 A AU 87009/98A AU 8700998 A AU8700998 A AU 8700998A AU 8700998 A AU8700998 A AU 8700998A
Authority
AU
Australia
Prior art keywords
apolipoprotein
polymorphism
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU87009/98A
Other versions
AU733237B2 (en
Inventor
Judes Poirier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU23006/95A external-priority patent/AU693193B2/en
Application filed by McGill University filed Critical McGill University
Priority to AU87009/98A priority Critical patent/AU733237B2/en
Publication of AU8700998A publication Critical patent/AU8700998A/en
Application granted granted Critical
Publication of AU733237B2 publication Critical patent/AU733237B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU87009/98A 1994-04-27 1998-09-23 Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease Ceased AU733237B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU87009/98A AU733237B2 (en) 1994-04-27 1998-09-23 Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9408465 1994-04-27
AU23006/95A AU693193B2 (en) 1994-04-27 1995-04-26 Use of apolipoprotein polymorphism e in the treatment of Alzheimer's disease
AU87009/98A AU733237B2 (en) 1994-04-27 1998-09-23 Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU23006/95A Division AU693193B2 (en) 1994-04-27 1995-04-26 Use of apolipoprotein polymorphism e in the treatment of Alzheimer's disease

Publications (2)

Publication Number Publication Date
AU8700998A true AU8700998A (en) 1998-12-03
AU733237B2 AU733237B2 (en) 2001-05-10

Family

ID=3712126

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87009/98A Ceased AU733237B2 (en) 1994-04-27 1998-09-23 Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease

Country Status (1)

Country Link
AU (1) AU733237B2 (en)

Also Published As

Publication number Publication date
AU733237B2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AU1407399A (en) Treatment for alzheimer's disease
HU9302551D0 (en) Compounds having effect against hypoglycemia and alzheimer's disease
AU5508798A (en) Diagnostic and therapeutic reagents for alzheimer's disease
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
AU3590897A (en) Traveler's quarters
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AU7397094A (en) Prevention and treatment of alzheimer's disease
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
AU1189395A (en) Apolipoprotein e polymorphism and alzheimer's disease
AU4775797A (en) Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease
AU7556994A (en) Methods for the diagnosis of alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
NO20001869D0 (en) Procedures for the treatment of Alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
EP1039883A4 (en) Methods for the treatment of apolipoprotein e related diseases
EP0866799A4 (en) Apolipoprotein e2 and treatment of alzheimer's disease
AU8700998A (en) Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
AU2002301084A1 (en) Identification of agents for use in the treatment of alzheimer's disease
AU1072195A (en) Diagnosis of alzheimer's disease
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)